Epaxal: a virosomal vaccine to prevent hepatitis A infection.
about
Vaccine Adjuvants: from 1920 to 2015 and BeyondClinical Translation of Nanomedicine.Potential applications and human biosafety of nanomaterials used in nanomedicineImmunogenicity and safety of a pediatric dose of a virosomal hepatitis A vaccine in healthy children in India.Successful memory response following a booster dose with a virosome-formulated hepatitis a vaccine delayed up to 11 yearsAn overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccinesDesign considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigensScience and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists.Reappraisal of the Immunogenicity and Safety of Three Hepatitis A Vaccines in Adolescents.Vaccine adjuvants: scientific challenges and strategic initiatives.Nanotherapeutics in the EU: an overview on current state and future directions.Pulmonary Delivery of Virosome-Bound Antigen Enhances Antigen-Specific CD4+ T Cell Proliferation Compared to Liposome-Bound or Soluble Antigen.Influenza virosomes as a vaccine adjuvant and carrier system.Therapeutic nanoparticles in clinics and under clinical evaluation.Combination of adjuvants: the future of vaccine design.Influenza virosomes as vaccine adjuvant and carrier system.Liposomal drug products and recent advances in the synthesis of supercritical fluid-mediated liposomes.Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature.The basics and advances of immunomodulators and antigen presentation: a key to development of potent memory response against pathogens.The impact of size on particulate vaccine adjuvants.Nanocarriers: a versatile approach for mucosal vaccine delivery.Virus-based nanoparticles as platform technologies for modern vaccines.Vaccine technologies: From whole organisms to rationally designed protein assemblies.Micro and Nano Material Carriers for Immunomodulation.An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice.Single-Dose Hepatitis A Immunization: 7.5-Year Observational Pilot Study in Nicaraguan Children to Assess Protective Effectiveness and Humoral Immune Memory Response.Adjuvant formulations for virus-like particle (VLP) based vaccines.The role of nanotechnology in the treatment of viral infections.Lipid interactions modulate the structural and antigenic properties of the C-terminal domain of the malaria antigen merozoite surface protein 2.Efficacy of hepatitis A vaccination and factors impacting on seroconversion in patients with inflammatory bowel disease.Stimulus-responsive liposomes as smart nanoplatforms for drug delivery applications.Nanoparticles in the clinic.Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation
P2860
Q26783879-A8CC73BE-74F7-49BD-B7D5-1533A1F17C4FQ30355939-CAD60943-8A81-46C1-8BD9-5BFBFC9BE7BBQ32944368-BF3D440F-8E86-4652-922D-4E5A439658C1Q34291194-4669ADA1-B99B-4913-BCD6-9A8A99ED46F8Q35066156-1AE7E33A-18B1-44FE-8BDC-CD33D0697B7BQ35100779-8667DDC7-AF6F-475D-9478-3A0A9F6C1890Q35812875-76A8DFA1-65FC-4553-98F0-7F0CE49A8999Q36394925-6159657B-4F35-4CE1-AF21-8CE5C658A502Q36461602-97684580-EE5D-49A8-8A31-963EA057F053Q37403484-5F8013D4-DCC0-4F7C-8D02-0396866F26DFQ37601242-83F1D619-E9F8-46D1-BE88-A87841AD7D9CQ37740679-6384DEB5-D682-446E-9120-50DE793273B9Q37867100-C174A63A-AE19-4934-99A3-AFFAA5338807Q38087986-61B9429B-16F7-4B4D-8EA9-B0626C658446Q38124060-C7BE73DF-BEC9-4BF5-BF31-E640D984135BQ38124062-409C37BB-3C9B-47FB-ACFF-3E3316A877C8Q38132414-495A3082-E370-4737-B843-91FCBDA38C42Q38186768-57C78CB2-9382-4BA7-A995-29B8F8091CA8Q38217630-FFBDF7EA-9BA9-4E85-B759-D3274D0D4215Q38296080-EA60EA3D-90EB-4CE1-AF4F-145298DF55B0Q38358876-061FFC38-ECC5-46D3-967D-83F2BDC19441Q38702017-DA894D02-D470-4001-B5D9-DDC5F30ACFB5Q38806558-715259A4-EC83-47A7-899A-EBD0E895A8ABQ38841904-E537833C-AAE2-4F96-B4F4-EF81AE6114CFQ38971243-EF67A516-CB43-4A55-8186-ED9B325FF3AFQ39228853-A3AF3C7D-AFB8-465A-BD80-85AD3F0EDD90Q40093469-5967DCE7-DF68-429E-9646-64AD507F5006Q40106774-B7896134-7323-473E-8ABA-AADF1783CC71Q40171072-FBEC6374-1689-4B2A-BB1A-F5BA4F543692Q42252569-66A08E33-DF09-4E14-A839-AD5C15D52536Q50060960-D3E8F8FA-8A33-4DDE-B4E8-D0D20470514CQ55003489-F461DA1E-F820-4026-A980-3EA1295D05A5Q56993652-B1AA1029-0B4A-4F43-8C32-8A9CB98F4E23
P2860
Epaxal: a virosomal vaccine to prevent hepatitis A infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Epaxal: a virosomal vaccine to prevent hepatitis A infection.
@en
Epaxal: a virosomal vaccine to prevent hepatitis A infection.
@nl
type
label
Epaxal: a virosomal vaccine to prevent hepatitis A infection.
@en
Epaxal: a virosomal vaccine to prevent hepatitis A infection.
@nl
prefLabel
Epaxal: a virosomal vaccine to prevent hepatitis A infection.
@en
Epaxal: a virosomal vaccine to prevent hepatitis A infection.
@nl
P2860
P1476
Epaxal: a virosomal vaccine to prevent hepatitis A infection.
@en
P2093
Patrick A Bovier
P2860
P304
P356
10.1586/14760584.7.8.1141
P577
2008-10-01T00:00:00Z